Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab

Inflammatory Bowel Diseases

Volumn 14, Issue 5, 2008, Pages 591-596

  Di Sabatino, Antonio ^a   Rosado, M Manuela ^b   Cazzola, Paolo ^a   Biancheri, Paolo ^a   Tinozzi, Francesco Paolo ^a   Laera, Maria Rita ^a   Cantoro, Laura ^a   Vanoli, Alessandro ^a   Carsetti, Rita ^b   Corazza, Gino Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Hyposplenism; Infection; Pitted red cell; Therapy; Tumor necrosis factor

Indexed keywords

IMMUNOGLOBULIN M; INFLIXIMAB; MESALAZINE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CELL COUNT; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEMORY CELL; PRIORITY JOURNAL; SPLEEN FUNCTION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MICROSCOPY, INTERFERENCE; MIDDLE AGED; SPLEEN; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 44349127287     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20374     Document Type: Article

References (25)

1. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-298.
2. Ryan FP, Smart RC, Holdsworth CD, et al. Hyposplenism in inflammatory bowel disease. Gut. 1978;19:50-55.
3. Palmer KR, Sherriff SB, Holdsworth CD, et al. Further experience of hyposplenism in inflammatory bowel disease. Q J Med. 1981;50:463-471.
4. Muller AF, Cornford E, Toghill PJ. Splenic function in inflammatory bowel disease: assessment by differential interference microscopy and splenic ultrasound. Q J Med. 1993;86:333-340.
5. Kruetzmann S, Rosado MM, Weber H, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med. 2003;197:939-945.
6. Di Sabatino A, Rosado MM, Ciccocioppo R, et al. Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am J Gastroenterol. 2005;100:1788-1795.
7. Ettinger R, Mebius R, Browning JL, et al. Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development. Int Immunol. 1998;10:727-741.
8. Pasparakis M, Kousteni S, Peschon J, et al. Tumor necrosis factor and the p55TNF receptor are required for optimal development of the marginal sinus and for migration of follicular dendritic cell precursors into splenic follicles. Cell Immunol. 2000;201:33-41.
9. Engwerda CR, Ato M, Cotterell SE, et al. A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am J Pathol. 2002;161:429-437.
10. Martin F, Kearney JF. Marginal-zone B cells. Nat Rev Immunol. 2002;2:323-335.
11. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-2972.
12. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
13. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995;20:27-32.
14. Corazza GR, Bullen AW, Hall R, et al. Simple method of assessing splenic function in coeliac disease. Clin Sci. 1981;60:109-113.
15. Smart RC, Ryan FP, Holdsworth CD, et al. Relationship between splenic size and splenic function. Gut. 1978;19:56-59.
16. Pereira JL, Hughes LE, Young HL. Spleen size in patients with inflammatory bowel disease. Does it have any clinical significance? Dis Colon Rectum. 1987;30:403-409.
17. + B cells are crucial in secondary immune response by producing high affinity IgM. Clin Immunol. 2003;108:128-137.
18. Liu YJ, Malisan F, de Bouteiller O, et al. Within germinal centers, isotype switching of immunoglobulins genes occurs after the onset of somatic mutation. Immunity. 1996;4:241-250.
19. Carsetti R, Rosado MM, Wardemann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004;197:179-191.
20. Cucino C, Sonnenberg A. The comorbid occurrence of other diagnosis in patients with ulcerative colitis and Crohn's disease. Am J Gastroenterol. 2001;96:2107-2112.
21. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
22. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285.
23. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease. Inflamm Bowel Dis. 2001;7:327.-
24. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J. 2002;78:47-48.
25. Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol. 2006;34:599-608.